Table 10.

Reduction in 10-year risk of major CVD end points (CHD death/non-fatal MI) in major statin trials, or substudies of major trials, in diabetic subjects (n = 16,032)

Study (ref.)	CVD prevention	Statin dose and comparator	Risk reduction (%)	Relative risk reduction (%)	Absolute risk reduction (%)	LDL cholesterol reduction
4S-DM (186)	2°	Simvastatin 20–40 mg vs. placebo	85.7 to 43.2	50	42.5	186 to 119 mg/dl (36%)
ASPEN 2° (191)	2°	Atorvastatin 10 mg vs. placebo	39.5 to 24.5	34	12.7	112 to 79 mg/dl (29%)
HPS-DM (187)	2°	Simvastatin 40 mg vs. placebo	43.8 to 36.3	17	7.5	123 to 84 mg/dl (31%)
CARE-DM (188)	2°	Pravastatin 40 mg vs. placebo	40.8 to 35.4	13	5.4	136 to 99 mg/dl (27%)
TNT-DM (189)	2°	Atorvastatin 80 mg vs. 10 mg	26.3 to 21.6	18	4.7	99 to 77 mg/dl (22%)
HPS-DM (187)	1°	Simvastatin 40 mg vs. placebo	17.5 to 11.5	34	6.0	124 to 86 mg/dl (31%)
CARDS (209)	1°	Atorvastatin 10 mg vs. placebo	11.5 to 7.5	35	4	118 to 71 mg/dl (40%)
ASPEN (191)	1°	Atorvastatin 10 mg vs. placebo	9.8 to 7.9	19	1.9	114 to 80 mg/dl (30%)
ASCOT-DM (190)	1°	Atorvastatin 10 mg vs. placebo	11.1 to 10.2	8	0.9	125 to 82 mg/dl (34%)

Studies were of differing lengths (3.3–5.4 years) and used somewhat different outcomes, but all reported rates of CVD death and non-fatal MI. In this tabulation, results of the statin on 10-year risk of major CVD end points (CHD death/non-fatal MI) are listed for comparison between studies. Correlation between 10-year CVD risk of the control group and the absolute risk reduction with statin therapy is highly significant (P = 0.0007). Analyses provided by Craig Williams, Pharm.D., Oregon Health & Science University, 2007.